Bulk Drug Park in the country :PIB
The financial assistance by the centre is subject to a maximum limit of Rs.1000 crore per park
The financial assistance by the centre is subject to a maximum limit of Rs.1000 crore per park
India exported about Rs 33,321 crore and imported Rs 35,249 crore worth APIs and Bulk drugs in 2021-22.
The NTM-001 Phase I clinical study is expected to be completed by the end of 2022
AstraZeneca and Indian Society of Nephrology aim to help clinicians and healthcare practitioners to provide holistic kidney care to their patients.
The region's digital health market, valued at USD 40.3 billion in 2021, is expected to expand to USD 326.7 billion by 2030 at a CAGR of 26.5 per cent.
Sun Pharma will receive from Cassiopea the exclusive right to develop and commercialize WINLEVI in Japan, Australia, New Zealand, Brazil, Mexico and Russia.
An outlay of Rs. 1,500 crore has been approved for strengthening/ up-gradation of these NIPERs for the period 2021-22 to 2025-26.
The Elecsys Amyloid Plasma Panel has the potential to ensure better identification of patients that require further confirmatory testing, supporting a more timely and accessible diagnosis.
The company now exceeds the sector benchmark for its overall ESG rating and for all three measures
Subscribe To Our Newsletter & Stay Updated